相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic characterization of mutations altering protein degradation in human cancers
Collin Tokheim et al.
MOLECULAR CELL (2021)
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
Timothy D. Martin et al.
SCIENCE (2021)
Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
Xiaoxia Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
The Complex Interplay between Antioxidants and ROS in Cancer
Isaac S. Harris et al.
TRENDS IN CELL BIOLOGY (2020)
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon-Cavanagh et al.
ESMO OPEN (2020)
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
Lea Berland et al.
JOURNAL OF THORACIC DISEASE (2019)
Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data
Samuel L. Wolock et al.
CELL SYSTEMS (2019)
Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1
Luca Lignitto et al.
CELL (2019)
Defining and Modulating 'BRCAness'
Andrea K. Byrum et al.
TRENDS IN CELL BIOLOGY (2019)
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
Jarostaw Przybycinski et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
The Immune Landscape of Cancer (vol 48, pg 812, 2018)
Vesteinn Thorsson et al.
IMMUNITY (2019)
In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients
Simon Heeke et al.
CANCERS (2019)
STING: a master regulator in the cancer-immunity cycle
Yuanyuan Zhu et al.
MOLECULAR CANCER (2019)
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
Antonio Marzio et al.
MOLECULAR CELL (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Buettner et al.
ESMO OPEN (2019)
Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints
Diana Saleiro et al.
SEMINARS IN IMMUNOLOGY (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
NRF2 and the Hallmarks of Cancer
Montserrat Rojo de la Vega et al.
CANCER CELL (2018)
An overview on Vadimezan (DMXAA): The vascular disrupting agent
Amir Daei Farshchi Adli et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer
Agnieszka Dansonka-Mieszkowska et al.
Oncotarget (2018)
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Rodrigo Romero et al.
NATURE MEDICINE (2017)
Type I Interferon in Chronic Virus Infection and Cancer
Laura M. Snell et al.
TRENDS IN IMMUNOLOGY (2017)
The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair
Petar Jelinic et al.
ONCOTARGET (2017)
Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families
Kirsi M. Maatta et al.
BMC CANCER (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131
Radhika A. Varier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing
Qi Chen et al.
NATURE IMMUNOLOGY (2016)
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Jacob H. Levine et al.
CELL (2015)
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition
Adrian P. Wiegmans et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31 (vol 53, pg 806, 2014)
Emmanuelle Vire et al.
MOLECULAR CELL (2014)
The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
Xin Cai et al.
MOLECULAR CELL (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
The emerging role of the Nrf2-Keap1 signaling pathway in cancer
Melba C. Jaramillo et al.
GENES & DEVELOPMENT (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY
Scott A. Ezella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Akt1, EMSY, BRCA2 and type I IFN signaling A novel arm of the IFN response
Scott A. Ezell et al.
TRANSCRIPTION-AUSTIN (2012)
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Ken Itoh et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Multitargeted inhibitors in lung cancer: New clinical data
Jair Bar et al.
CLINICAL LUNG CANCER (2008)
Fluorescent proteins as proteomic probes
IM Cristea et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
L Hughes-Davies et al.
CELL (2003)
分享论文
